之江生物
(688317)
| 流通市值：30.41亿 | | | 总市值：30.41亿 |
| 流通股本：1.90亿 | | | 总股本：1.90亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 53,388,232.75 | 25,419,230.44 | 124,818,624.7 | 90,432,870.13 |
| 营业收入 | 53,388,232.75 | 25,419,230.44 | 124,818,624.7 | 90,432,870.13 |
| 二、营业总成本 | 99,895,489.51 | 57,769,206 | 191,336,369.74 | 142,500,155.06 |
| 营业成本 | 18,656,583.42 | 7,916,025.78 | 44,743,521.27 | 33,798,967.18 |
| 税金及附加 | 3,761,134.14 | 1,899,376.55 | 1,235,873.24 | 5,815,089.08 |
| 销售费用 | 15,523,333.3 | 9,072,612.64 | 50,345,636.96 | 31,199,209.62 |
| 管理费用 | 33,228,105.59 | 17,918,244.21 | 79,683,253.8 | 60,968,812.72 |
| 研发费用 | 24,730,821.45 | 11,586,524.45 | 50,869,097.23 | 42,058,199.29 |
| 财务费用 | 3,995,511.61 | 9,376,422.37 | -35,541,012.76 | -31,340,122.83 |
| 其中:利息费用 | 2,682,217.29 | 1,418,201.53 | 3,487,750.58 | 2,077,626.74 |
| 其中:利息收入 | 35,073,850.18 | 10,447,245.46 | 62,074,366.72 | 44,853,872.55 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,443,309.15 | 204,000 | 2,360,210.85 | - |
| 加:投资收益 | 2,445,020.94 | 1,881,212.14 | 3,821,335.22 | 2,804,908.46 |
| 资产处置收益 | 188,474.37 | - | 44,975.63 | 25,777.74 |
| 资产减值损失(新) | -686,248.21 | 6,256,893.34 | 10,775,110.55 | 15,328,545.94 |
| 信用减值损失(新) | 2,055,144.19 | 225,003.38 | -4,277,724.37 | 1,168,467.86 |
| 其他收益 | 667,441.86 | 197,332.06 | 6,219,464.79 | 5,183,354.15 |
| 四、营业利润 | -40,394,114.46 | -23,585,534.64 | -47,574,372.37 | -27,556,230.78 |
| 加:营业外收入 | 1,620,980.37 | 306,298.42 | 7,131,174.82 | 3,173,484.83 |
| 减:营业外支出 | 840,255.72 | 617,431.81 | 1,673,248.94 | 1,555,511.25 |
| 五、利润总额 | -39,613,389.81 | -23,896,668.03 | -42,116,446.49 | -25,938,257.2 |
| 减:所得税费用 | 976,015.23 | 1,613,579.39 | -7,818,879.94 | 3,439,598.75 |
| 六、净利润 | -40,589,405.04 | -25,510,247.42 | -34,297,566.55 | -29,377,855.95 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -40,589,405.04 | -25,510,247.42 | -34,297,566.55 | -29,377,855.95 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -40,589,405.04 | -25,510,247.42 | -34,297,566.55 | -29,377,855.95 |
| 扣除非经常损益后的净利润 | -45,207,295.62 | -27,145,069.41 | -49,109,772.39 | -37,251,605.63 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.23 | -0.15 | -0.19 | -0.16 |
| (二)稀释每股收益 | -0.23 | -0.15 | -0.19 | -0.16 |
| 八、其他综合收益 | -3,069,771.16 | -2,004,953.83 | -988,720.13 | 42,222.59 |
| 归属于母公司股东的其他综合收益 | -3,069,771.16 | -2,004,953.83 | -988,720.13 | 42,222.59 |
| 九、综合收益总额 | -43,659,176.2 | -27,515,201.25 | -35,286,286.68 | -29,335,633.36 |
| 归属于母公司股东的综合收益总额 | -43,659,176.2 | -27,515,201.25 | -35,286,286.68 | -29,335,633.36 |
| 公告日期 | 2026-08-28 | 2026-04-30 | 2026-04-24 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |